Exelixis Inc Amortization of Debt Discount (Premium)
Exelixis Inc (EXEL) reported Amortization of Debt Discount (Premium) of $5.29 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2016-05-04
- Exelixis Inc amortization of debt discount (premium) for the quarter ending 2016-03-31 was $5.29M, a 31.14% decline year-over-year.
- Exelixis Inc amortization of debt discount (premium) for the quarter ending 2015-12-31 was $4.84M, a 37.21% decline year-over-year.
- Exelixis Inc amortization of debt discount (premium) for the quarter ending 2015-09-30 was $5.30M, a 29.39% decline year-over-year.
- Exelixis Inc amortization of debt discount (premium) for the quarter ending 2015-06-30 was $7.22M, a 1.53% decline year-over-year.
- Exelixis Inc amortization of debt discount (premium) for fiscal 2015 was $25.03M, a 15.24% decline from fiscal 2014.
- Exelixis Inc amortization of debt discount (premium) for fiscal 2014 was $29.53M, a 12.34% increase from fiscal 2013.
- Exelixis Inc amortization of debt discount (premium) for fiscal 2013 was $26.29M, a 78.21% increase from fiscal 2012.
- Exelixis Inc amortization of debt discount (premium) for fiscal 2012 was $14.75M, a 84.65% increase from fiscal 2011.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2016-03-31 | $5.29M 10-Q · filed 2016-05-04 | $10.13M derived: sum of 2 quarters · filed 2016-05-04 | $15.43M derived: sum of 3 quarters · filed 2016-05-04 | $22.64M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $10.14M derived: sum of 2 quarters · filed 2016-02-29 | $17.36M derived: sum of 3 quarters · filed 2016-02-29 | $25.03M 10-K · filed 2016-02-29 |
| 2015-09-30 | $5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $12.52M derived: sum of 2 quarters · filed 2015-11-10 | $20.19M 10-Q · filed 2015-11-10 | $27.90M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-06-30 | $7.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $14.89M 10-Q · filed 2015-08-11 | $22.60M derived: sum of 3 quarters · filed 2016-05-04 | $30.11M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-03-31 | $7.67M 10-Q · filed 2016-05-04 | $15.38M derived: sum of 2 quarters · filed 2016-05-04 | $22.89M derived: sum of 3 quarters · filed 2016-05-04 | $30.22M derived: sum of 4 quarters · filed 2016-05-04 |
| 2014-12-31 | $7.71M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $15.22M derived: sum of 2 quarters · filed 2016-02-29 | $22.55M derived: sum of 3 quarters · filed 2016-02-29 | $29.53M 10-K · filed 2016-02-29 |
| 2014-09-30 | $7.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $14.84M derived: sum of 2 quarters · filed 2015-11-10 | $21.83M 10-Q · filed 2015-11-10 | $28.67M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $7.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $14.32M 10-Q · filed 2015-08-11 | $21.16M derived: sum of 3 quarters · filed 2016-02-29 | $27.81M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $6.99M 10-Q · filed 2015-04-30 | $13.83M derived: sum of 2 quarters · filed 2016-02-29 | $20.48M derived: sum of 3 quarters · filed 2016-02-29 | $26.96M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $13.50M derived: sum of 2 quarters · filed 2016-02-29 | $19.98M derived: sum of 3 quarters · filed 2016-02-29 | $26.29M 10-K · filed 2016-02-29 |
| 2013-09-30 | $6.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $13.13M derived: sum of 2 quarters · filed 2014-11-04 | $19.45M 10-Q · filed 2014-11-04 | $25.57M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $6.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $12.79M 10-Q · filed 2014-07-31 | $18.92M derived: sum of 3 quarters · filed 2015-03-02 | $23.07M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $6.31M 10-Q · filed 2014-05-01 | $12.44M derived: sum of 2 quarters · filed 2015-03-02 | $16.59M derived: sum of 3 quarters · filed 2015-03-02 | $18.87M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $6.13M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $10.28M derived: sum of 2 quarters · filed 2015-03-02 | $12.56M derived: sum of 3 quarters · filed 2015-03-02 | $14.75M 10-K · filed 2015-03-02 |
| 2012-09-30 | $4.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $6.43M derived: sum of 2 quarters · filed 2013-10-30 | $8.62M 10-Q · filed 2013-10-30 | |
| 2012-06-30 | $2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $4.48M 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | $2.19M 10-Q · filed 2013-05-07 | |||
| 2011-12-31 | $7.99M 10-K · filed 2014-02-20 | |||
| 2010-12-31 | $3.60M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |